CEL-SCI study in Oral Oncology flags low PD-L1, N0 oral cancer patients for Multikine survival benefit
Reuters2026/08/04 12:02- CEL-SCI published peer-reviewed results in Oral Oncology from its IT-MATTERS trial; results were already presented in the journal publication.
- Study supports using low or zero PD-L1 expression and no lymph node involvement to identify oral cancer patients most likely to benefit from Multikine.
- Biomarker-selected patients treated with Multikine before surgery showed better survival outcomes than standard care alone, supporting a differentiated positioning versus checkpoint inhibitors.
- Enrollment is being prepared for a 212-patient global confirmatory registration study in the same biomarker-defined population to validate the earlier survival benefit.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
